Danaher (NYSE:DHR) Given New $265.00 Price Target at Stifel Nicolaus

Danaher (NYSE:DHR) had its price objective increased by Stifel Nicolaus from $250.00 to $265.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Stifel Nicolaus currently has a hold rating on the conglomerate’s stock.

DHR has been the subject of a number of other research reports. Evercore ISI increased their price target on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Stephens began coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective for the company. Barclays reduced their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Wells Fargo & Company began coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Trading Down 1.1 %

Shares of DHR stock opened at $245.39 on Wednesday. The stock has a 50-day simple moving average of $269.52 and a 200 day simple moving average of $260.42. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The stock has a market capitalization of $181.76 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the company posted $2.02 EPS. Danaher’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, sell-side analysts expect that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,059 shares of company stock valued at $8,400,897. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DHR. Vanguard Group Inc. increased its position in Danaher by 7.4% in the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after buying an additional 4,163,657 shares during the period. Swedbank AB bought a new position in Danaher in the 1st quarter worth approximately $676,545,000. TD Asset Management Inc increased its position in Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA increased its position in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after buying an additional 563,546 shares during the period. Finally, International Assets Investment Management LLC increased its position in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.